The biomarkers your doctor isn't tracking yet

Fasting insulin can sit elevated for a decade while your glucose reads flawless the entire time. That’s not a rounding error; it’s the standard panel’s blind spot. The pancreas quietly cranks out more and more insulin to hold the line, the glucose passes every check, and by the time the glucose finally drifts up you’ve already spent ten years of compensation nobody measured. The marker that would have caught it costs about as much as the one that didn’t, and almost no one orders it.

Ask for “the full workup” and you’ll get a lipid panel, a CBC, a metabolic panel, maybe a thyroid number. Fifteen markers, give or take. It’s a competent screen for disease you might already have, and a poor map of where you’re heading. The markers that move first, the ones that flash years before anything trips a flag, usually aren’t on the order sheet unless you know the names.

Think of a standard panel as the dashboard warning lights in an old car: oil, temperature, battery. They’re binary, and they come on late. By the time the light is lit, the damage is already underway. The markers below are the gauges, not the lights. They show you the needle climbing while there’s still room to act. Here are the four I’d add first.

Four markers your doctor isn’t tracking yet

ApoB. Each atherogenic particle carries a single ApoB protein, so ApoB counts the particles while LDL-C only weighs the cholesterol inside them. The count is what tracks who has the heart attack. They come apart in the people who can least afford it: insulin-resistant folks whose LDL-C reads calm while their particle count runs high. Why ApoB beats LDL-C, and the evidence behind it, is its own post. You measure it precisely to find out which group you’re in.

Fasting insulin. Glucose tells you when the system has already failed. Insulin tells you how hard it’s working to look fine. This is the marker I’d fight hardest to keep on the list.

hsCRP. Low-grade inflammation runs underneath most chronic disease, and high-sensitivity CRP is the cheapest window onto it we have. The catch is that it’s noisy. A cold, a hard leg day, a bad night’s sleep will all bump it, so a single reading is close to meaningless. You want it measured a few times, away from acute illness, and read as a trend.

Lp(a). Largely genetic, set near birth, and a risk multiplier that a large fraction of people carry without ever being told. You measure it once. If it’s high, it reframes how you read every other number, and it’s almost never ordered.

The number alone is half the story

Here’s where one marker becomes a finding. Take that fasting insulin sitting at, say, 14 µIU/mL with a perfectly normal fasting glucose of 90 mg/dL. On its own, the glucose looks great and most panels would stop there. Read the two together and the picture inverts. Normal glucose held up by high insulin isn’t health, it’s a system straining to stay normal. That’s exactly the moment the early-warning set exists to catch.

Now layer in time and a second domain. That fasting insulin at 14 µIU/mL is one needle reading. What makes it actionable is lining it up against an HbA1c that crept from 5.2 to 5.5% across two draws, and against a sleep log showing a months-long habit of late, carb-heavy snacks before bed. Insulin up, three-month glucose average up, late eating up: three signals pointing the same way. None of them alarming alone. Together they’re a slope, and a slope you can bend. Cut the bedtime snack, and the trajectory is the thing to watch, not the single number.

Why they get skipped

The fair objection: if these markers are so useful, why doesn’t your doctor order them? It isn’t malice or ignorance. It’s the slot. A fifteen-minute visit is built to rule out acute disease today, not to chart a trajectory over years. Markers that need repetition, context, and interpretation don’t fit that slot, and a system that pays for problems rather than slopes has no reason to make them fit. For most people, most of the time, the cheap panel is a reasonable bet. It comes apart exactly when it matters most, and the only way to know if that’s you is to look.

So look. Add ApoB and fasting insulin to your next draw, get Lp(a) once and file it, and treat hsCRP as a trend rather than a verdict. Then do the thing a panel can’t do for you: put them next to each other, and next to the last reading, and watch which way the needle is moving. The point of a measurement was never to pass or fail today. It’s to catch the gauge climbing while the warning light is still dark.